The New Challenge For The Architect Of Wegovy

Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.

Mads Thomsen
Mads Krogsgaard Thomsen • Source: Novo Nordisk Foundation

Few people are better placed to comment on the phenomenon that is Novo Nordisk A/S's stunning growth in the past couple years with Ozempic and Wegovy than Mads Krogsgaard Thomsen, the man who supervised the development of the diabetes and obesity blockbusters and is now the CEO of the foundation that controls the Danish drugmaker.

Thomsen, who served over 20 years as chief scientific officer at the Copenhagen-based group, was appointed as CEO of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By 

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

More from Leadership

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.